A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

March 27, 2025

Conditions
Chronic SinusitisNasal Polyps
Interventions
DRUG

TQC2731 injection

TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

DRUG

TQC2731 matching placebo

It'a a placebo injection without active substances.

Trial Locations (16)

116001

Affiliated Zhongshan Hospital Of Dalian University, Dalian

200031

Eye & ENT Hospital of Fudan University, Shanghai

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

241000

The First Affiliated Hospital of Wannan Medical College, Wuhu

261041

Weifang Second People's Hospital, Weifang

266000

The Affiliated Hospital of Qingdao University, Qingdao

510280

ZhuJiang Hospital of Southern Medical University, Guangzhou

519000

The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai

522000

Jieyang People's Hospital, Jieyang

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

610000

Chengdu Second People's Hospital, Chengdu

610041

West China Hospital of Sichuan University, Chengdu

710100

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

830000

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

061000

Cangzhou Central Hospital, Cangzhou

010000

Affiliated Hospital of Inner Mongolia Medical University, Hohhot

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY